Bactocillin® is a food supplement containing the probiotic strain Bifidobacterium breve PRL2020, the only bacterial strain available on worldwide market with demonstrated resistance to high concentrations of the antibiotics Amoxicillin and Amoxicillin/Clavulanic acid.
This unique feature allows Bactocillin® to be administered simultaneously with these two antibiotics, with the aim of counteracting the re-emergence of pathogenic bacteria and consequently reducing the incidence of diarrhoea and intestinal disorders during antibiotic treatment, while preventing post-antibiotic relapses. The genome of B. breve PRL2020 has been fully sequenced and its safety for use has been established.

Scientific reference(s)

Mancabelli L, Mancino W, Lugli GA, Argentini C, Longhi G, Milani C, Viappiani A, Anzalone R, Bernasconi S, van Sinderen D, Ventura M, Turroni F. Amoxicillin-Clavulanic Acid Resistance in the Genus Bifidobacterium. Appl Environ Microbiol. 2021 Mar 11;87(7):e03137-20. doi: 10.1128/AEM.03137-20. PMID: 33483308; PMCID: PMC8091617.

Additional info

Therapeutical area(s)

Gastrointestinal tract


Anti-inflammatory activity · Antipathogenic activity


Children · Adults

Dosage form



15 billion(s)

Take full advantage of MicrobiomePost's features